Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To investigate the effect of artificial liver blood purification treatment on the survival of severe/critical patients with COVID‐19.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>A total of 101 severe and critical patients with SARS‐CoV‐2 infection were enrolled in this open, case‐control, multicentre, prospective study. According to the patients' and their families' willingness, they were divided into two groups. One was named the treatment group, in which the patients received artificial liver therapy plus comprehensive treatment, while the other was named the control group, in which the patients received only comprehensive treatment. Clinical data and laboratory examinations, as well as the 28‐day mortality rate, were collected and analysed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>This study involved 101 severe/critical patients with COVID‐19, among which 50 were in the treatment group and 51 were in the control group. Baseline data comparisons on average age, sex, pre‐treatment morbidity, initial symptoms, vital signs, pneumonia severity index (PSI) score, blood routine examination and biochemistry indices et al. showed no difference between the two groups. Cytokine storm was detected, with a significant increase of serum IL‐6 level. The serum IL‐6 level decreased from 119.94 pg/mL to 20.49 pg/mL in the treatment group and increased from 40.42 pg/mL to 50.81 pg/mL in the control group (p<0.05), indicating that artificial liver therapy significantly decreased serum IL‐6. The median duration of viral nucleic acid persistence was 19 days in the treatment group (ranging from 6‐67 days) and 17 days in the control group (ranging from 3‐68 days), no significant difference was observed (p=0.36). As of 28‐day follow‐up,17 patients in the treatment group experienced a median weaning time of 24 days, while 11 patients in the control group experienced a median weaning time of 35 days, with no significant difference between the two groups (p=0.33). The 28‐day mortality rates were 16% (8/50) in the treatment group and 50.98% (26/51) in the control group, with a significant difference (z=3.70, p<0.001).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Cytokine storm is a key factor in the intensification of COVID‐19 pneumonia. The artificial liver therapy blocks the cytokine storm by clearing inflammatory mediators, thus preventing severe cases from progressing to critically ill stages and markedly reducing short‐term mortality.</p></section>

The role of artificial cells in the fight against COVID-19: deliver vaccine, hemoperfusion removes toxic cytokines, nanobiotherapeutics lower free radicals and pCO2 and replenish blood supply

Application Value of Artificial Liver Support System in the Treatment of Cytokine Storm in Patients with COVID-19

Hemoperfusion Based on Artificial Cells for Aluminium and Iron Removal, Immunosorption, Fulminant Hepatic Failure, Uremia, Poisoning and Metabolic Assists

Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe and Critical COVID-19

The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19

Current status in cellular-based therapies for prevention and treatment of COVID-19

Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation

A Review of Extracorporeal Blood Purification Techniques for the Treatment of Critically Ill Coronavirus Disease 2019 Patients

Cell-Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy.

Cell‐Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy

The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences

Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines

Stem cell therapy for COVID‐19: Possibilities and challenges

New directions of scientific research and clinical practice in the field of extracorporeal hemocorrection in patients with multiple organ dysfunction: a review

Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?

Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review

Blood purification therapy in patients with severe COVID-19 requiring veno-venous ECMO therapy: A retrospective study

The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness

Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review

Effect of artificial liver blood purification treatment on the survival of critical ill COVID‐19 patients

When Stem Cells Meet COVID-19: Recent Advances, Challenges and Future Perspectives